ELIZABETH, N.J.--(BUSINESS WIRE)--May 8, 1996--Faulding Inc.'s wholly owned subsidiary Purepac Pharmaceutical Co. has received approval from the Food and Drug Administration to market diflunisal tablets, it was announced today by Richard F. Moldin, president and chief executive officer of Faulding Inc.
Diflunisal is an oral non-steroidal drug with analgesic, anti-inflammatory, and antipyretic properties. It is used extensively in the treatment of acute or long-term mild to moderate pain, osteoarthritis, and rheumatoid arthritis.
"Our new 250 mg and 500 mg tablets are the bioequivalent of Dolobid(R) Tablets. Total 1995 brand and generic sales were estimated at nearly $20 million," Moldin said. "This new drug is the second FDA approval received by the company in the last two months," he added.
Faulding Inc. was formerly Purepac, Inc., an oral generic drug producer which changed its name following its recent expansion by acquisition beyond oral drugs into generic injectable drugs and devices. The shares of Faulding Inc. are traded on NASDAQ under the symbol "FAUL." -0- Note: Dolobid(R) is a registered trademark of Merck & Co.
CONTACT: Faulding Inc., Elizabeth
Lee Craker, 908/527-9100
COPYRIGHT 1996 Business Wire
COPYRIGHT 2004 Gale Group
Contact
Home
A
Dacarbazine